Insmed (Insmed) Days Payable : 323.50 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Insmed Days Payable?

Insmed's average Accounts Payable for the three months ended in Dec. 2023 was $65.4 Mil. Insmed's Cost of Goods Sold for the three months ended in Dec. 2023 was $18.4 Mil. Hence, Insmed's Days Payable for the three months ended in Dec. 2023 was 323.50.

The historical rank and industry rank for Insmed's Days Payable or its related term are showing as below:

INSM' s Days Payable Range Over the Past 10 Years
Min: 233.1 Med: 303.98 Max: 2441.27
Current: 326.85

During the past 13 years, Insmed's highest Days Payable was 2441.27. The lowest was 233.10. And the median was 303.98.

INSM's Days Payable is ranked better than
70.31% of 714 companies
in the Biotechnology industry
Industry Median: 149.875 vs INSM: 326.85

Insmed's Days Payable increased from Dec. 2022 (216.58) to Dec. 2023 (323.50). It may suggest that Insmed delayed paying its suppliers.

Insmed Days Payable Historical Data

The historical data trend for Insmed's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Days Payable Chart

Insmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

233.10

256.49

325.04

285.52

322.44

Insmed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															216.58	353.42	308.96	330.67	323.50

Competitive Comparison of Insmed's Days Payable

For the Biotechnology subindustry, Insmed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insmed's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Days Payable distribution charts can be found below:

* The bar in red indicates where Insmed's Days Payable falls into.

Insmed Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Insmed's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (50.461	+	65.393)	/	2 )	/	65.573	*	365
=	57.927					/	65.573	*	365
=	322.44

Insmed's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (65.377	+	65.393)	/	2 )	/	18.443	*	365 / 4
=	65.385					/	18.443	*	365 / 4
=	323.50

Insmed Days Payable Related Terms

Thank you for viewing the detailed overview of Insmed's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed (Insmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

INSM:Mexico IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Executives

Flammer Martina M.d.	officer: Chief Medical Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett	officer: Chief Commercial Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise	officer: Chief Commercial Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith	officer: General Counsel, Senior VP	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis	officer: President & CEO	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole	officer: Chief People Strategy Officer	INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano	officer: Chief Compliance Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari	officer: General Counsel & Secretary	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807